Enabling the Nervous System to Repair Itself

Episode Summary

Executive Summary: This episode examines NerveGen Pharma’s effort to develop NVG291, a peptide therapy aimed at enabling nervous system repair after spinal cord injury by blocking CSPG-driven inhibition. CEO Mike Kelly explains the biology, the company’s human safety data, its ongoing efficacy trial, and why spinal cord injury is the lead indication before broader neurodegenerative applications like stroke, MS, and ALS.

Main Topics: Unmet need in spinal cord injury (Priority: 5/5): The discussion frames spinal cord injury as a common, life-altering condition with no FDA-approved drugs that restore function, leaving rehabilitation as the main option. CSPGs and inhibited repair (Priority: 5/5): Kelly explains how chondroitin sulfate proteoglycans accumulate after injury, creating an inhibitory environment that blocks axonal sprouting, remyelination, and regeneration. NVG291 mechanism and development (Priority: 5/5): NVG291 is described as a peptide that blocks signaling from CSPGs, effectively 'inhibiting the inhibitor' to support neural repair; it has animal efficacy and completed phase 1 human safety testing. Clinical strategy and trial progress (Priority: 4/5): NerveGen is pursuing a phase 1B/2A study in chronic spinal cord injury first, with subacute patients to follow, and expects to use results to support future development and financing. Pipeline beyond spinal cord injury (Priority: 4/5): The company sees potential in stroke, multiple sclerosis, and ALS, but plans to validate the approach in spinal cord injury before expanding into other indications. Funding and public-company challenges (Priority: 3/5): Kelly discusses the realities of being a small public company with limited resources, recent financing, and the need to raise additional capital after data readout.

Key Arguments: Spinal cord injury remains a major unmet medical need because there are no FDA-approved therapies that repair the nervous system after injury. After spinal cord injury, CSPGs accumulate and create an inhibitory scar-like environment that prevents axon growth and remyelination. NVG291 may reverse that inhibition by blocking CSPG signaling, allowing the body to repair itself more effectively. The molecule has shown efficacy in multiple animal models and was shown to be safe in a human phase 1 study, supporting progression to efficacy testing. NerveGen chose spinal cord injury first because its animal data are strongest there, the regulatory path is clearer, and the founding story is closely tied to this indication. The same biological mechanism could apply to other CNS diseases such as stroke, MS, and ALS, but the company must sequence development due to limited resources. Being public has not hindered NerveGen materially; shareholder support and recent financing have helped, though more capital will be needed after trial data.

Data Points: Annual spinal cord injuries in the U.S.: 18,000 to 19,000 - Mike Kelly describes the incidence of new spinal cord injuries each year in the United States. People living with spinal cord injury in the U.S.: Roughly 300,000 - Kelly cites the prevalent population affected by spinal cord injury. Global yearly spinal cord injuries: About 500,000 - The intro notes the worldwide burden of spinal cord injury. Share of patients who are men: 75% - Kelly says most spinal cord injury patients are men. Typical age at injury: Early 40s - He notes the demographic profile of many patients. Post-injury recovery window: 9 to 12 months - Kelly says improvement typically occurs only during the first year before plateauing. Phase 1 study status: Completed last year - NerveGen completed a human safety study for NVG291. Clinical trial phase: Phase 1B/2A - The company is currently running an efficacy-focused trial in spinal cord injury. Recent financing: $23 million - Kelly says NerveGen completed a financing in Canada several months earlier. Initial public raise: $10 million in 2019 - The company went public with a relatively small raise for an early-stage asset. Cash runway: Through Q3 2025 - Kelly states current cash is sufficient into the third quarter of 2025. Study duration: 16 weeks - He describes the ongoing clinical study as 16 weeks long. Chronic injury cohort: 1 to 10 years after injury - The first study group consists of chronic spinal cord injury patients.

Pivotal Quotes: "There are no drugs available to treat patients today." — Mike Kelly: He explains the current treatment landscape for spinal cord injury. "What NVG291 does is it inhibits the inhibitor." — Mike Kelly: He summarizes the drug’s mechanism of action in simple terms. "We had to pick a lane and we pick spinal cord as our first venture into human clinical trials." — Mike Kelly: He explains why NerveGen is prioritizing spinal cord injury over other indications.

Implications: If NVG291 succeeds, it could become one of the first therapies to actively promote CNS repair after spinal cord injury and open a broader platform in stroke, MS, and ALS. Near-term, trial data and financing will be pivotal for the company’s valuation and development path.